Temozolomide for treatment of brain metastases: A review of 21 clinical trials

Table 3 Treatment administration and clinical outcomes of the studies that used temozolomide as a single agent

Trial	Cancer	Treatment administration			Clinical outcomes
		Drug	Dose regimen	Mediancycles	CR	PR	OR	ORR	SD	PD	Other (median1)
1	NSCLC (n = 22) Breast (n = 10) Melanoma (n = 3) SCLC (n = 2) Rectal (n = 2) Ovarian (n = 1) Endometrial (n = 1)	TMZ	150-200 mg/m2 per day, days 1-5/28-d cycle	NA	0	22	2	0.059	15 (82/43/34)	17 (92/33/54)	TTP: 1.97 mo OS: 6.62 mo
2	Melanoma (n = 53) Breast cancer (n = 51) NSCLC (n = 53)	TMZ	150 mg/m2 per day, days 1-7, 15-21/28- or 35-d cycle	NA	12	9 (55/23/22)	10	0.064	31 (125/83/112)	116 (365/413/392)	PFS: 56 d5/58 d3/66 d2 OS: 100 d5/172 d2
3	Melanoma	TMZ	125-150 mg/m2 per day, days 1-7, 15-21/28-d cycle	48 d	0/06	2/16	2/16	0.044/ 0.0276	5/56	33/316	OS: 4.1 mo (3.6 mo8/4.3 mo7)
4	NSCLC	TMZ	150-200 mg/m2 per day, days 1-5/28-d cycle	6	2	1	3	0.1	3	24	TTP: 3.6 mo OS: 6 mo
5	NSCLC (n = 12) SCLC (n = 5) Breast (n = 4) Other (n = 7)	TMZ	150 mg/m2 per day, days 1-5/28-d cycle	NA	0	1	1	0.042	4	19	TTP: 3 mo OS: 4.5 mo
6	Melanoma	TMZ	150-200 mg/m2 per day, days 1-5/28-d cycle	NA	1	8	9	0.074	40	73	PFS: 1.2 mo7/1.0 mo8 OS: 3.5 mo7/2.2 mo8
7	NSCLC	TMZ	200 mg/m2 per day , days 1-5/28-d cycle	1	0	0	0	0	3	8	NA

¹Median: Data here are median values;

²NSCLC;

³Breast cancer;

⁴Other cancer;

⁵Melanoma;

⁶Extracerebral response;

⁷No prior chemotherapy;

⁸Prior chemotherapy. TMZ: Temozolomide; NA: Not available; NSCLC: Non–small cell lung cancer; SCLC: Small cell lung cancer; SD: Stable disease; PR: Partial response; CR: Complete response; OR: Objective response; ORR: Objective response rate; PD: Progressive disease; PFS: Progression-free survival; TTP: Time to progression; OS: Overall survival.